IVフラッシュシリンジの世界市場-2022-2029

市場力学

IVフラッシュシリンジにおけるイノベーションが市場成長の原動力となることが期待されます。

ダブルチャンバーシリンジは、医薬品とデバイスのコンボ製品として、あらかじめ定義された量の医薬品を簡単に再構成して投与できるようにするために作られたものです。すでにプレフィルドされているフラッシュ液と薬剤を充填する必要のある空室の2液を投与することが多いため、現在販売されている複数液投与用シリンジの多くはあまり歓迎されていません。しかし、通常の薬液投与とその後のカテーテル洗浄を同時に行えるシリンジはなく、広く普及が進んでいます。今回開発した2室型シリンジは、この市場のギャップを補い、薬液と洗浄液を同時に充填・供給することを可能にします。また、このシリンジを使用することで、看護師が点滴の際にフラッシュを行うことが容易になり、準備や投与時間の短縮、カテーテルの調整回数の減少、PIVC関連のトラブル減少などの効果が期待されます。したがって、上記の記述から、予測期間中に市場を牽引することが期待されます。

IVフラッシュシリンジに関連する合併症は、市場成長の妨げになると予想されます。

空気塞栓症は、1つまたは複数の気泡が動脈または静脈に入り、血流が制限されたときに発症します。注射器や点滴によって、誤って静脈に空気が注入されることがあります。空気塞栓症の大部分は良性で、ごくわずかな症状が出るか、まったく症状が出ません。空気塞栓症は、通常、悪影響を及ぼすことなく、自然に治ります。しかし、空気塞栓症は非常にまれで、脳、心臓、肺に影響を与えることはほとんどありません。もし、空気塞栓症が発生した場合、心臓発作、脳卒中、呼吸不全を引き起こす可能性があります。

さらに、塩化ナトリウム洗浄の副作用として、体液過多とアレルギー反応の2つがより深刻です。比較的まれなことではありますが、どちらも致命的であり、洗浄用シリンジの回収を増加させる可能性があります。したがって、上記の記述から、予測期間中に市場が阻害されることが予想されます。

産業分析

IVフラッシュシリンジ市場は、サプライチェーン分析、価格分析などの様々な産業要因に基づいて、市場の詳細な分析を提供します。

COVID-19の影響分析

COVID-19の大流行は、ヘルスケアシステムと市場にプラスの影響を与えています。薬剤師や看護師などの医療従事者は、世界のCOVID-19の大流行により、大きな心理的、感情的、身体的影響を受けています。さらに、臨床従事者は追加の個人防護具（PPE）を着用しなければなりませんが、ウイルスの伝染性のために可動域や反応時間が制限される可能性があります。そのため、薬剤の準備や投与にミスが生じる可能性が高くなります。RTA（Ready-to-Administer：すぐに使える薬剤）の活用は、医師の負担を軽減し、複雑な薬剤調製手順を最小限に抑えるための戦略の一つです。例えば、プレフィルドシリンジやその他のRTAアイテムは、生産性を大幅に向上させるとともに、ミスや患者への傷害の可能性を最小限に抑えることができます。

一方、2022年3月21日現在、米国食品医薬品局（FDA）は、0.9%の塩化ナトリウム（生理食塩水）を含むプレフィルド静脈（IV）ロック/フラッシュシリンジが国内で不足していることを認識しています。COVID-19公衆衛生緊急事態における需要の高まりと、その後の一部のプレフィルド生理食塩水ロック/フラッシュシリンジの永久製造中止を含むベンダーのサプライチェーンの困難さにより、プレフィルド0.9パーセント塩化ナトリウム静脈ロック/フラッシュシリンジは不足しています。したがって、上記の記述から、予測期間中に市場が盛り上がると予想されます。

当レポートでは、世界のIVフラッシュシリンジ市場について、約45以上の市場データ表、40以上の図表、160ページにわたるアクセスを提供します。

目次

第1章 調査手法と調査範囲

• 調査手法
• 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場の力学

• 市場影響要因
  • 促進要因
    • IVフラッシュシリンジにおけるイノベーションが市場成長を促進すると予想されます。
  • 抑制要因
    • IVフラッシュシリンジに関連する合併症が市場成長を阻害すると予想されます。
  • 市場機会
  • 影響分析

第5章 産業分析

• サプライチェーン分析
• 価格設定分析

第6章 COVID-19の分析

• COVID-19の市場分析
  • COVID-19以前の市場シナリオ
  • COVID-19の現在の市場シナリオ
  • COVID-19の後、または将来のシナリオ
• COVID-19の中での価格ダイナミクス
• 需要-供給スペクトラム
• パンデミック時の市場に関連する政府の取り組み
• メーカーの戦略的な取り組み
• まとめ

第7章 タイプ別

• 生理食塩水用点滴筒
• ヘパリンIVフラッシュシリンジ

第8章 エンドユーザー別

• 病院
• クリニック
• 外来手術センター
• その他

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ地域

第10章 競合情勢

• 主な展開と戦略
• 企業シェア分析
• 製品ベンチマーク
• 注目の主要企業リスト

第11章 企業プロファイル

• B. Braun Melsungen AG
  • 企業概要
  • 製品ポートフォリオと説明
  • 主なハイライト
  • 財務概要
• R. A. Caldwell Co. Inc.
• Becton, Dickinson and Company
• Cardinal Health
• Nipro Corporation
• Aquabiliti
• Medline Industries, LP
• Medefil, Inc.
• Polymedicure
• SteriCare Solutions

第12章 IVフラッシュシリンジの世界市場-DataM

Market Overview

IV Flush Syringe Market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 5.7 % during the forecast period (2022-2029).

IV flush syringes are common medical devices used to clear intravenous lines. Saline flushes are generally safe and well tolerated by patients when administered properly. Millions of patients use it daily to clean intravenous lines. This makes it more likely that medications will be completely absorbed, won't mix inside the tube, and that blood there won't clot. Saline IV flush syringes and heparin IV flush syringes are the two types of IV flush syringes.

Market Dynamics

Innovation in the IV flush syringes is expected to drive market growth.

Double-chamber syringes have been created as a medicine and device combo product to make it easier to reconstitute and administer pharmaceuticals in predefined amounts. Since they frequently call for the delivery of two fluids, one flush solution that has already been prefilled and an empty chamber that needs to be filled with medication, many of the currently available syringes sold for the administration of multiple fluids have not been well welcomed. However, no syringe that enables filling both chambers simultaneously, one for ordinary medication administration and the other for a subsequent catheter flush, has acquired broad popularity. A double-chamber syringe is created to cover this market gap and allow for the filling and delivery of medication and flush solution. Moreover, the novel syringe is expected to make it easier for nurses to implement best clinical practices during intravenous medication administration, such as flushing, cutting down on preparation and administration time, reducing the number of catheter adjustments, and lowering PIVC-related problems. Thus, from the above statements, the market is expected to drive in the forecast period.

Complications associated with IV Flush Syringe are expected to hamper the market growth.

An air embolism develops when one or more air bubbles enter an artery or vein and restrict blood flow. A syringe or IV can inadvertently inject air into a vein. The majority of air embolisms are benign, producing very subtle symptoms or none at all. These typically go away on their own without having any negative effects. However, air embolisms are extremely rare and rarely affect the brain, heart, or lungs. If they do, a heart attack, stroke, or respiratory failure could result.

Moreover, fluid overload and an allergic reaction are two more severe side effects of a sodium chloride flush. Despite being relatively uncommon, both can be fatal and increase recalls of flush syringes. Thus, from the above statements, the market is expected to get hampered in the forecast period.

Industry Analysis

The IV flush syringe market provides in-depth analysis of the market based on various industry factors such as supply chain analysis, pricing analysis etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has positively impacted healthcare systems and the market. Health care professionals, such as pharmacists and nurses, have experienced significant psychological, emotional, and physical effects due to the global COVID-19 pandemic. Moreover, clinical workers must wear additional personal protective equipment (PPE) that might restrict their range of motion and reaction time due to the virus's contagious nature. This raises the likelihood of mistakes occurring when medications are prepared and administered. Utilizing ready-to-administer (RTA) medications is one strategy to ease physicians' workload and minimize complicated drug preparation steps. Prefilled syringes and other RTA items, for instance, can significantly improve productivity while minimizing mistakes and possible patient injury.

In contrast, as of March 21, 2022, the U.S. Food and Drug Administration (FDA) is aware that there are shortages of prefilled intravenous (IV) lock/flush syringes that contain 0.9 percent sodium chloride (saline) in the country. Due to a rise in demand during the COVID-19 public health emergency and subsequent vendor supply chain difficulties, including the permanent discontinuation of some prefilled saline lock/flush syringes, there is a shortage of prefilled 0.9 percent sodium chloride IV lock/flush syringes. Thus, from the above statements, the market is expected to boost in the forecast period.

Segment Analysis

Saline IV Flush Syringe segment is expected to hold the largest market share in IV Flush Syringe market

The saline IV flush syringe segment is expected to dominate in 2021. The segment benefits because the hazards of microbial contamination that arise when doses are drawn up at the ward level are eliminated by the use of prefilled saline syringes. Additionally, the chance of incorrect selection is decreased by the completely labeled nature of prefilled syringes. The time saved by nurses is another important issue. Ad hoc preparation of intravenous dosages incurs costs (including disposables and nurse time) that are frequently disregarded but can pile up in a busy ward. According to one study, using prefilled syringes reduced nursing time by 42% compared to using traditional injection systems.

Further, under the NPSA recommendation, Northampton General Hospital introduced prefilled saline syringes early this year as a part of a broader push to reduce the use of heparin flushes. The NPSA Alert 20, Promoting Safer Use of Injectable Medicines, served as the starting point and contained several action items and suggested actions to increase the safety of injectable medications. Therefore, it has increased the demand for saline IV flush syringes. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global IV flush syringe market

In 2021, North America accounted for the highest revenue share. The increasing inpatient admissions for chronic diseases, rising surgical procedures, the high adoption of the IV flush syringe, well-established infrastructure and product launches and acquisitions by the region's key market players are some factors the market is expected to boost in the forecast period. For instance, heart disease is the leading cause of death for both sexes and members of most racial and ethnic groups in the United States. Cardiovascular disease claims one life in the United States every 34 seconds. In the United States, heart disease claimed the lives of almost 697,000 people in 2020, accounting for 1 in 5 fatalities. Patients with heart disease who experience an aggravation must be admitted to the hospital and given special care. The strong demand for these syringes is expected to be influenced by this issue.

Moreover, BD (Becton, Dickinson and Company) announced in October 2021 that it had strengthened the US government's access to safe injection devices by boosting production. The public-private cooperation between BD and the Assistant Secretary for Preparedness and Response at the Department of Health and Human Services (HHS) created the new syringe and needle manufacturing lines (ASPR). Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the IV flush syringe market are B. Braun Melsungen AG, R. A. Caldwell Co. Inc., Becton, Dickinson and Company, Cardinal Health, Nipro Corporation, Aquabiliti, Medline Industries, LP, Medefil, Inc., Polymedicure, SteriCare Solutions.

B. Braun Melsungen AG:

Overview:

B. Braun is a German manufacturer of medical and pharmaceutical devices. The B. Braun product line includes 5,000 items, 95 percent of which are manufactured by the company. The company's product portfolio includes infusion, nutrition, pain therapy products, infusion pumps and systems, surgical instruments, suture materials, hip and knee implants, dialysis equipment and accessories, ostomy, disinfection, and wound care products. The company operates its business through five divisions: hospital care, Aesculap, B. Braun Avitum, out-patient market (OPM) and other sales. B. Braun has a presence in 64 countries and develops products in 18 therapy fields of the healthcare industry.

Product Portfolio:

Omniflush with SwabCap: A standard saline intravenous flush syringe with an integrated SwabCap is called an Omniflush with SwabCap. A SwabCap is a luer access valve cap with a 70% isopropyl alcohol disinfection concentration. For the user's convenience, they are incorporated together. The purpose of SwabCap is to serve as a cover for swab-able Luer access valves, shielding them from potential contamination. The SwabCap is a cleaning disinfectant before line access and a physical barrier to contamination between line accesses. SwabCap will disinfect the valve thirty (30) seconds after application and maintains a disinfected valve surface for up to seven (7) days if not removed.

The global IV flush syringe market report would provide an access to an approx. 45+market data table, 40+figures and 160pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Innovation in the IV flush syringes is expected to drive market growth.
  • 4.1.2. Restraints:
    • 4.1.2.1. Complications associated with IV Flush Syringe are expected to hamper the market growth.
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Supply Chain Analysis
• 5.2. Pricing Analysis

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type Segment
• 7.2. Saline IV Flush Syringe*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Heparin IV Flush Syringe

8. By End user

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 8.1.2. Market Attractiveness Index, By End user Segment
• 8.2. Hospitals*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Clinics
• 8.4. Ambulatory Surgical Center
• 8.5. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.2.5.1. U.S.
    • 9.2.5.2. Canada
    • 9.2.5.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.3.5.1. Germany
    • 9.3.5.2. U.K.
    • 9.3.5.3. France
    • 9.3.5.4. Italy
    • 9.3.5.5. Spain
    • 9.3.5.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.4.5.1. Brazil
    • 9.4.5.2. Argentina
    • 9.4.5.3. Rest of South America
• 9.5. Asia Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.5.5.1. China
    • 9.5.5.2. India
    • 9.5.5.3. Japan
    • 9.5.5.4. Australia
    • 9.5.5.5. Rest of Asia Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

10. Competitive Landscape

• 10.1. Key Developments and Strategies
• 10.2. Company Share Analysis
• 10.3. Product Benchmarking
• 10.4. List of Key Companies to Watch

11. Company Profiles

• 11.1. B. Braun Melsungen AG*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Key Highlights
  • 11.1.4. Financial Overview
• 11.2. R. A. Caldwell Co. Inc.
• 11.3. Becton, Dickinson and Company
• 11.4. Cardinal Health
• 11.5. Nipro Corporation
• 11.6. Aquabiliti
• 11.7. Medline Industries, LP
• 11.8. Medefil, Inc.
• 11.9. Polymedicure
• 11.10. SteriCare Solutions

LIST NOT EXHAUSTIVE

12. Global IV Flush Syringe Market - DataM

• 12.1. Appendix
• 12.2. About Us and Applications
• 12.3. Contact Us